413 related articles for article (PubMed ID: 17394811)
21. Biological therapy.
Roberts L
Nurs Stand; 2004 Nov 17-23; 19(10):21. PubMed ID: 15612428
[No Abstract] [Full Text] [Related]
22. Infliximab treatment failure in a case of cutaneous Crohn's disease.
Yang DJ; Hsu S
J Am Acad Dermatol; 2005 Nov; 53(5):903-4. PubMed ID: 16243156
[No Abstract] [Full Text] [Related]
23. Innovative uses of rituximab in dermatology.
Carr DR; Heffernan MP
Dermatol Clin; 2010 Jul; 28(3):547-57. PubMed ID: 20510764
[TBL] [Abstract][Full Text] [Related]
24. Key developments in dermatology.
Stollery NA
Practitioner; 2003 Feb; 247(1643):75, 79, 82 passim. PubMed ID: 12621801
[No Abstract] [Full Text] [Related]
25. Learning curve.
Weinberg JM
Cutis; 2003 Nov; 72(5):349. PubMed ID: 14655770
[No Abstract] [Full Text] [Related]
26. Use of biological response modifiers to enhance the action of Rituximab.
Taylor RP
Leuk Res; 2005 Jun; 29(6):599-600. PubMed ID: 15863194
[No Abstract] [Full Text] [Related]
27. The role of biologics and other systemic agents in the treatment of pediatric psoriasis.
Wright NA; Piggott CD; Eichenfield LF
Semin Cutan Med Surg; 2010 Mar; 29(1):20-7. PubMed ID: 20430304
[No Abstract] [Full Text] [Related]
28. [Up-date on the use of infliximab in dermatology. Introduction].
Sánchez-Carazo J
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():1. PubMed ID: 19080984
[No Abstract] [Full Text] [Related]
29. Topical immunomodulators in dermatology.
Khandpur S; Sharma VK; Sumanth K
J Postgrad Med; 2004; 50(2):131-9. PubMed ID: 15235214
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous B-cell lymphoma treated with rituximab infusions.
Schneider LA
Acta Derm Venereol; 2006; 86(6):550-1. PubMed ID: 17106608
[No Abstract] [Full Text] [Related]
31. [Low-grade cutaneous B-cell lymphoma: Failure of intralesional rituximab (Mabthera)].
Abasq C; Duval-Modeste AB; Courville P; Joly P
Ann Dermatol Venereol; 2008; 135(6-7):509-11. PubMed ID: 18598807
[No Abstract] [Full Text] [Related]
32. Navigating Targeted Therapeutics in Dermatology: Biologics and Small Molecules.
Costello C; Maarouf M; Shi V
J Drugs Dermatol; 2018 Dec; 17(12):1330-1332. PubMed ID: 30586268
[TBL] [Abstract][Full Text] [Related]
33. Key developments in dermatology.
Smith V; Sharpe G
Practitioner; 2005 Jun; 249(1671):398, 400, 402 passim. PubMed ID: 15966274
[No Abstract] [Full Text] [Related]
34. Biosimilars in dermatology: starting with infliximab.
Puig L
Actas Dermosifiliogr; 2013 Apr; 104(3):175-80. PubMed ID: 23218608
[No Abstract] [Full Text] [Related]
35. Prospects for the use of differentiation-modulating agents as adjuvant of photodynamic therapy for proliferative dermatoses.
Akilov OE; Kosaka S; Maytin EV; Hasan T
J Dermatol; 2008 Apr; 35(4):197-205. PubMed ID: 18419676
[TBL] [Abstract][Full Text] [Related]
36. [Cytostatic and immunosuppressive treatment of dermatologic diseases].
Braun-Falco O; Burg G
Ther Ggw; 1971 Apr; 110(4):488-500. PubMed ID: 4930022
[No Abstract] [Full Text] [Related]
37. Coexistent psoriasis and lupus erythematosus treated with alefacept.
Berthelot C; Nash J; Duvic M
Am J Clin Dermatol; 2007; 8(1):47-50. PubMed ID: 17298107
[TBL] [Abstract][Full Text] [Related]
38. Practical experience of biologics for treatment of very severe psoriasis: a retrospective case cohort study of patients with a baseline Psoriasis Area and Severity Index greater than 20.
Ponnambath N; Kalavala M; Anstey AV; Piguet V; Ingram JR
Clin Exp Dermatol; 2016 Jan; 41(1):95-6. PubMed ID: 25817265
[No Abstract] [Full Text] [Related]
39. [The use of retinoids in dermatology].
Brzezińska-Wcisło L; Pierzchała E; Kamińska-Budzińska G; Bergler-Czop B; Trzmiel D
Wiad Lek; 2004; 57(1-2):63-9. PubMed ID: 15181752
[TBL] [Abstract][Full Text] [Related]
40. A case of rituximab-related urticarial reaction in cutaneous B-cell lymphoma.
Rey J; Wickenhauser S; Ivanov V; Coso D; Gastaut JA; Bouabdallah R
J Eur Acad Dermatol Venereol; 2009 Feb; 23(2):210. PubMed ID: 18482321
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
